176 related articles for article (PubMed ID: 22313737)
21. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
22. Knockdown of Forkhead box A1 suppresses the tumorigenesis and progression of human colon cancer cells through regulating the phosphatase and tensin homolog/Akt pathway.
Pan J; Xu Z; Xu M; Lin X; Lin B; Lin M
J Int Med Res; 2020 Dec; 48(12):300060520971453. PubMed ID: 33296605
[TBL] [Abstract][Full Text] [Related]
23. Forkhead box A1 (FOXA1) is a key mediator of insulin-like growth factor I (IGF-I) activity.
Potter AS; Casa AJ; Lee AV
J Cell Biochem; 2012 Jan; 113(1):110-21. PubMed ID: 21882221
[TBL] [Abstract][Full Text] [Related]
24. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.
Habashy HO; Powe DG; Rakha EA; Ball G; Paish C; Gee J; Nicholson RI; Ellis IO
Eur J Cancer; 2008 Jul; 44(11):1541-51. PubMed ID: 18538561
[TBL] [Abstract][Full Text] [Related]
25. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA‑212 inhibits the proliferation and invasion of human renal cell carcinoma by targeting FOXA1.
Tong Z; Meng X; Wang J; Wang L
Mol Med Rep; 2018 Jan; 17(1):1361-1367. PubMed ID: 29115609
[TBL] [Abstract][Full Text] [Related]
27. Association of FOXA1 and EMT markers (Twist1 and E-cadherin) in breast cancer.
BenAyed-Guerfali D; Dabbèche-Bouricha E; Ayadi W; Trifa F; Charfi S; Khabir A; Sellami-Boudawara T; Mokdad-Gargouri R
Mol Biol Rep; 2019 Jun; 46(3):3247-3255. PubMed ID: 30941644
[TBL] [Abstract][Full Text] [Related]
28. Role of transcription factor FOXA1 in non‑small cell lung cancer.
Li J; Zhang S; Zhu L; Ma S
Mol Med Rep; 2018 Jan; 17(1):509-521. PubMed ID: 29115441
[TBL] [Abstract][Full Text] [Related]
29. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical evaluation of forkhead box A1 and EphA5 markers in serous ovarian carcinomas, and their impact on the clinical outcome of patients.
Abouhashem N; Harb O; Elwan A; Zaitoun M; Saraya Y
Pol J Pathol; 2022; 73(2):120-133. PubMed ID: 36345952
[TBL] [Abstract][Full Text] [Related]
31. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.
Albergaria A; Paredes J; Sousa B; Milanezi F; Carneiro V; Bastos J; Costa S; Vieira D; Lopes N; Lam EW; Lunet N; Schmitt F
Breast Cancer Res; 2009; 11(3):R40. PubMed ID: 19549328
[TBL] [Abstract][Full Text] [Related]
32. Lack of both androgen receptor and forkhead box A1 (FOXA1) expression is a poor prognostic factor in estrogen receptor-positive breast cancers.
Park S; Koh E; Koo JS; Kim SI; Park BW; Kim KS
Oncotarget; 2017 Oct; 8(47):82940-82955. PubMed ID: 29137314
[TBL] [Abstract][Full Text] [Related]
33. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
34. High Throughput Chemical Screening Reveals Multiple Regulatory Proteins on FOXA1 in Breast Cancer Cell Lines.
Wang S; Singh SK; Katika MR; Lopez-Aviles S; Hurtado A
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30572598
[TBL] [Abstract][Full Text] [Related]
35. FOXA1 is an independent prognostic marker for ER-positive breast cancer.
Mehta RJ; Jain RK; Leung S; Choo J; Nielsen T; Huntsman D; Nakshatri H; Badve S
Breast Cancer Res Treat; 2012 Feb; 131(3):881-90. PubMed ID: 21503684
[TBL] [Abstract][Full Text] [Related]
36. Down-regulated FOXA1 in early-onset pre-eclampsia induces apoptosis, and inhibits migration and invasion of trophoblast cells.
Zhu J; Wei Y; Wang Z; Jie Q; Sun F; Li Q; Long P; Huang Y; Yu Y; Ma Y
J Gene Med; 2020 Dec; 22(12):e3273. PubMed ID: 32894789
[TBL] [Abstract][Full Text] [Related]
37. Staufen1 Represses the FOXA1-Regulated Transcriptome by Destabilizing FOXA1 mRNA in Colorectal Cancer Cells.
Pasterczyk KR; Li XL; Singh R; Zibitt MS; Hartford CCR; Pongor L; Jenkins LM; Hu Y; Zhao PX; Muys BR; Kumar S; Roper N; Aladjem MI; Pommier Y; Grammatikakis I; Lal A
Mol Cell Biol; 2024; 44(2):43-56. PubMed ID: 38347726
[TBL] [Abstract][Full Text] [Related]
38. FOXA1 is a key determinant of estrogen receptor function and endocrine response.
Hurtado A; Holmes KA; Ross-Innes CS; Schmidt D; Carroll JS
Nat Genet; 2011 Jan; 43(1):27-33. PubMed ID: 21151129
[TBL] [Abstract][Full Text] [Related]
39. LncRNA TUG1 promotes cell proliferation and suppresses apoptosis in osteosarcoma by regulating miR-212-3p/FOXA1 axis.
Xie C; Chen B; Wu B; Guo J; Cao Y
Biomed Pharmacother; 2018 Jan; 97():1645-1653. PubMed ID: 29793327
[TBL] [Abstract][Full Text] [Related]
40. Efp promotes in vitro and in vivo growth of endometrial cancer cells along with the activation of nuclear factor-κB signaling.
Sato W; Ikeda K; Urano T; Abe Y; Nakasato N; Horie-Inoue K; Takeda S; Inoue S
PLoS One; 2018; 13(12):e0208351. PubMed ID: 30586414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
